{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:03:09Z","timestamp":1780905789377,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Linezolid is a gram-positive oral antibiotic whose duration-dependent risk of thrombocytopenia has historically constrained durations of therapy to &amp;lt;3 weeks. This study aimed to evaluate whether therapeutic drug monitoring (TDM)\u2013based management of linezolid can support prolonging the course of therapy for complex infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study included patients \u226518 years old discharged on linezolid for a planned duration of \u22653 weeks between January 1, 2023, and April 1, 2025. The primary outcome was early discontinuation of linezolid due to thrombocytopenia, compared between patients managed with TDM and matched controls without TDM, using 1:1 matching based on planned treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred sixty-two patients were included, with 81 in each study arm. The mean duration of linezolid (SD) was 32.1 (12.4) days, and 100 (62%) patients were treated for bone and joint infections. Patients receiving TDM were significantly more likely to be age \u226565 years, have recent surgery, receive Complex Outpatient Antimicrobial Therapy (COpAT) monitoring, have longer inpatient courses, and have additional laboratory monitoring performed. The primary outcome of early discontinuation from thrombocytopenia occurred in 11 (14%) patients vs 25 (31%) patients in the TDM and control arms, respectively (adjusted odds ratio, 0.07; 95% CI, 0.02\u20130.26). Thrombocytopenia remained the most common toxicity in both cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Linezolid TDM was associated with markedly lower rates of early discontinuation from thrombocytopenia, underscoring the potential value of early TDM and selective dose adjustment to enhance tolerability during prolonged treatment courses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag318","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:35:25Z","timestamp":1779190525000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7763-1712","authenticated-orcid":false,"given":"Jeffrey M","family":"Harrington","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerod L","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sallerson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9383-9326","authenticated-orcid":false,"given":"Xuping","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-4238","authenticated-orcid":false,"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Division of Infectious Diseases, University of Michigan Medical School , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-7407","authenticated-orcid":false,"given":"Vincent D","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3000-844X","authenticated-orcid":false,"given":"Beth","family":"Lawless","sequence":"additional","affiliation":[{"name":"Department of Pathology, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath P","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Eschenauer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026060803513830300_ofag318-B1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14787210.2.1.51","article-title":"A review of linezolid: the first oxazolidinone antibiotic","volume":"2","author":"Stevens","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026060803513830300_ofag318-B2","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1128\/AAC.01729-10","article-title":"LEADER program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States","volume":"55","author":"Farrell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060803513830300_ofag318-B3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026060803513830300_ofag318-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement","volume":"50","author":"Lovering","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2026060803513830300_ofag318-B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/joc.2010.22.1.17","article-title":"Linezolid penetration into cerebrospinal fluid and brain tissue","volume":"22","author":"Tsona","year":"2010","journal-title":"J Chemother"},{"key":"2026060803513830300_ofag318-B6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","article-title":"Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2026060803513830300_ofag318-B7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00542-17","article-title":"Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers","volume":"61","author":"Garrabou","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060803513830300_ofag318-B8","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00533-24","article-title":"Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets","volume":"68","author":"Milosevic","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026060803513830300_ofag318-B9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2026060803513830300_ofag318-B10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026060803513830300_ofag318-B11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2026060803513830300_ofag318-B12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jcpt.13359","article-title":"Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients","volume":"46","author":"Dai","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026060803513830300_ofag318-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the therapeutic range","volume":"44","author":"Abdul-Aziz","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2026060803513830300_ofag318-B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106783","article-title":"LInezolid monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring","volume":"61","author":"Lau","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026060803513830300_ofag318-B15","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/jamia\/ocaf073","article-title":"Supporting rapid innovation in research data capture and management: the REDCap external module framework","volume":"32","author":"Cheng","year":"2025","journal-title":"J Am Med Inform Assoc"},{"key":"2026060803513830300_ofag318-B16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2026060803513830300_ofag318-B17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2026060803513830300_ofag318-B18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ejhpharm-2022-003258","article-title":"Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients","volume":"31","author":"Qin","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"2026060803513830300_ofag318-B19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J Infect Chemother"},{"key":"2026060803513830300_ofag318-B20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","article-title":"Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy","volume":"73","author":"Chen","year":"2012","journal-title":"Curr Ther Res Clin Exp"},{"key":"2026060803513830300_ofag318-B21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/antibiotics10050530","article-title":"Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers","volume":"10","author":"Thirot","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026060803513830300_ofag318-B22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bcpt.13123","article-title":"Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases","volume":"124","author":"Choi","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag318\/68363421\/ofag318.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag318\/68363421\/ofag318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag318\/68363421\/ofag318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:51:45Z","timestamp":1780905105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag318\/8690138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag318","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,21]]},"article-number":"ofag318"}}